Biogen Q1 2024 results surpass expectation despite revenue decline

Biogen Inc. (NASDAQ: BIIB), a leading biotechnology company, has released its Q1 2024 financial results, showcasing resilience and strategic growth despite facing revenue challenges. In the first quarter of 2024, Biogen reported a revenue of $2.29 billion, which slightly missed expectations by $30 million. However, the company demonstrated a meaningful improvement in both gross and […]